Pomalidomide (trade name: Imnovid) has been approved since 2013 for the treatment of multiple myeloma that has returned and is difficult to treat. The drug is an option for adults who have received two or more prior treatment ...
Jan 12, 2016
0
1
A landmark Phase II study led by Winship Cancer Institute of Emory University and instrumental in the recent approval of a new multiple myeloma treatment was published online today in The Lancet, one of the oldest and most ...
Jan 6, 2016
0
2
One of the biggest questions about the treatment of multiple myeloma, a form of blood cancer, is why nearly all patients treated with current therapies eventually suffer relapse. A Yale Cancer Center study may have solved ...
Dec 8, 2015
0
11
A first-in-human Phase I study of multiple myeloma patients combined expanded cord blood-derived natural killer cells with transplantation of a patient's own stem cells and high-dose chemotherapy with little or none of the ...
Dec 7, 2015
0
73
Yale Cancer Center researchers have developed a vaccine strategy that reduces the risk of flu infections in cancer patients at highest risk for influenza. The findings were presented Dec. 6 at the 57th annual meeting of the ...
Dec 7, 2015
0
3
(HealthDay)—Empliciti (elotuzumab), in combination with two other drugs, has been approved by the U.S. Food and Drug Administration to treat the blood cancer multiple myeloma. The drug is only approved for patients who ...
Nov 30, 2015
0
1
A personalized method for testing the effectiveness of drugs that treat multiple myeloma may predict quickly and more accurately the best treatments for individual patients with the bone marrow cancer. The process, developed ...
Nov 20, 2015
0
19
Pevonedistat is a first-in-class, investigational small-molecule inhibitor of the NEDD8-activating enzyme, explained Shah. "This enzyme is part of the ubiquitin-proteasome system, which is the target of a number of FDA-approved ...
Nov 11, 2015
0
22
The risk of kidney failure caused by multiple myeloma appears to be declining, and survival is lengthening for patients who do develop kidney failure due to this cancer. The findings, which are published in a study appearing ...
Oct 29, 2015
0
13
Even patients with health insurance who have multiple myeloma may be vulnerable to "financial toxicity" – including those who make over $100,000 a year – because of the higher use of novel therapeutics and extended duration ...
Sep 30, 2015
0
11
